NMRD
Nemaura Medical Inc. [NMRD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NMRD Stock Summary
Top 10 Correlated Stocks
NMRD
In the News
NMRD Financial details
Company Rating
-
Market Cap
2.46M
Income
-6.3M
Revenue
-1.55M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
36
Optionable
No
Shortable
Yes
Earnings
22 Feb 2024
P/E
-0.4
Forward P/E
-
PEG
0.06
P/S
-1.79
P/B
-0.17
P/C
-
P/FCF
-0.28
Quick Ratio
0.09
Current Ratio
0.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.22
EPS next Y
-
EPS next Q
-
EPS this Y
71.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
79.81%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
53%
ROC
0.7%
Gross Margin
296%
Oper. Margin
568%
Profit Margin
447%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.068-1.25
52W High
-
52W Low
-
RSI
77.44
Rel Volume
0.02
Avg Volume
39.83K
Volume
745
Perf Week
100%
Perf Month
100%
Perf Quarter
-99.3%
Perf Half Y
-99.29%
-
-
-
-
Beta
-0.063
-
-
Volatility
0%, 0%
Prev Close
100%
Price
0.0002
Change
100%
Company Profile
- Volume Average 39.83K
- Market Capitalization 2.46M
- Employee 36
- CEO Dr. Dewan Fazlul Hoque Chowdhury Ph.D.
- Headquarters New York,NY,US
- IPO Date 2018-02-05
-
Website
https://nemauramedical.com 
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
